Immunotherapy for multiple myeloma: Current status and future directions

Ayed, Ayed O.; Chang, Lung‐Ji; Moreb, Jan S.

doi:10.1016/j.critrevonc.2015.06.006

Cited by 25 publications

(24 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In recent years, there has been much focus on the MM immunotherapies such as immunomodulatory drugs (IMiDS), allogeneic stem cell transplants (allo-SCT), monoclonal antibodies, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T cell therapy, dendritic cell (DC)-based vaccines, cytokine-induced killer cells (CIKs), and tumor infiltration lymphocytes (TILs) [7, 10, 24, 25]. However, the anti-BCMA CAR-T cells seem to be the most promising one so far.…”

Section: Car-t Cells Targeting Bcma Immunotherapy Shows Promisementioning

confidence: 99%

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma

Shi

Liu

2019

Ann Hematol

View full text Add to dashboard Cite

Multiple myeloma (MM) remains an incurable plasma cells malignancy because of its complex genetic heterogeneity and high relapse rate post immunotherapy. The encouraging results of chimeric antigen receptor T cell (CAR-T) targeting B cell maturation antigen (BCMA) immunotherapy clinical trials have shed light on curing MM in recent years. However, many therapeutic side effects limit the promotion and clinical use of this novel effective approach such as cytokine release syndrome, antigen escape, and neurotoxicity. We should make every effort to do further study about this immunotherapy to make it safer and effective. This review focusing on this topic clarifies the following contents: present status of MM treatment, effectiveness of CAR-T cells, features of BCMA, preclinical and clinical trials of BCMA CAR-T cells therapy, and existing problems and strategies. Hoping to provide a reference for the subsequent correlative clinical and research.

show abstract

Section: Car-t Cells Targeting Bcma Immunotherapy Shows Promisementioning

confidence: 99%

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma

Shi

Liu

2019

Ann Hematol

View full text Add to dashboard Cite

show abstract

“…In the last decades, the intervention of numerous approaches such as autologous stem cell transplantation, PIs, mAbs, and IMiDs have significantly improved patient outcomes and survivals, especially in younger patients, indicating the crucial roles of immune cell response in disease control . However, MM remains incurable and novel immunotherapies are urgently needed . Many protocols have been developed to reestablish a functional immune system by targeting to activate specific immune cells.…”

Section: Novel Nk Cell‐based Immunotherapiesmentioning

confidence: 99%

Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

Liu

Jin

Sattar

et al. 2018

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Multiple myeloma (MM) is a complex aggressive mature B-cell malignancy. Although with the wide application of chemotherapy drugs, it remains incurable and the vast majority of patients relapse. Natural killer (NK) cells, also known as CD56 CD3 large granular lymphocytes, are cytotoxic innate immune cells against MM without prior sensitization steps. NK cell-based immunotherapy is extensively promising in a wide range of clinical settings. It is worthy of note that some novel drugs such as monoclonal antibodies (mAbs), proteasome inhibitors (PIs), and immunomodulators (IMiDs) directly or indirectly activate NK cells to enhance their antitumor activity, and the combined regimens significantly improve the prognosis of MM patients. In this review, we summarize recent findings that support a role for NK cells in the pathogenesis of MM and outline innovative approaches in the implementation of NK cell-based immunotherapy against MM.

show abstract

“…6 The management of MM has been revolutionized over the last few years and this has been based on understanding recent advances in MM pathophysiology, discovery of new target pathways and development of novel therapeutic agents. 7 Over the last nine years, Albert Einstein Hospital (São Paulo, SP, Brazil), in collaboration with MD Anderson…”

Section: Introductionmentioning

confidence: 99%

Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study

et al. 2016

View full text Add to dashboard Cite

CONTEXT AND OBJECTIVE: For the last nine years, hematologists and oncologists have gathered annually at an educational symposium organized by a Brazilian and an American hospital. During the 2015 Board Review, a survey among the attendees evaluated the differences in management and treatment methods for multiple myeloma (MM). DESIGN AND SETTING: Cross-sectional study during an educational hematology symposium in São Paulo, Brazil. METHODS: Hematologists present at the symposium gave responses to an electronic survey by means of mobile phone. RESULTS: Among the 350 attendees, 217 answered the questionnaire. Most of the participants believed that immunotargeting agents (iTA) might be effective for slowing MM progression in heavily pretreated patients (67%) and that continued exposure to therapy might lead to emergence of resistant clones in patients with MM (76%). Most of the physicians use maintenance therapy after hematopoietic stem cell transplantation (95%) and 45% of them would further restrict it to post-transplantation patients with underlying high-risk disease. The first-line drugs used for transplantation-ineligible patients (TI-MM) were bortezomib-thalidomide-dexamethasone (31%), bortezomib-dexamethasone (28%), lenalidomide-dexamethasone (Rd; 17%) and melphalan-based therapy (10%). Lenalidomide was the drug of choice for post-transplantation maintenance for half of the participants. No significant differences were observed regarding age or length of experience. CONCLUSION: The treatment choices for TI-MM patients were highly heterogenous and the melphalan-based regimen represented only 10% of the first-line options. Use of maintenance therapy after transplantation was a common choice. Some results from the survey were divergent from the evidence in the literature.

show abstract

Immunotherapy for multiple myeloma: Current status and future directions

Cited by 25 publications

References 153 publications

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma

Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma

Natural killer cell immunotherapy against multiple myeloma: Progress and possibilities

Hematological approaches to multiple myeloma: trends from a Brazilian subset of hematologists. A cross-sectional study

Contact Info

Product

Resources

About